Research ArticleHIV

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

See allHide authors and affiliations

Science Translational Medicine  20 Sep 2017:
Vol. 9, Issue 408, eaao4235
DOI: 10.1126/scitranslmed.aao4235

Swatting away a swarm

Monoclonal antibodies are being tested as therapy for many infections, including HIV. However, increasing evidence suggests that therapy with a single agent may encourage resistant viral strains to emerge. Julg et al. tested how potent HIV neutralizing antibodies could combat challenge with a mix of SHIV strains in nonhuman primates. They found that monotherapy with anti-V3 PGT121 or anti-V2 PGDM1400 allowed for selection of resistant viruses and subsequent replication in the animals. Dual antibody administration conferred complete protection, confirming that combination therapy may be necessary for protective efficacy against HIV in people.